While the majority of AD therapeutic efforts advanced in clinical trials have been focused on targeting amyloid and tau, neuroprotective strategies are developed to target at degenerative mechanisms triggered by or involving factors mentioned above. Here, MAPT is linked to Alzheimer disease.